Beta-blockers and physical frailty in patients with end-stage liver disease

Table 3 Competing risks survival analysis

Variable	Univariable SHR (95%CI)	Multivariable SHR (95%CI)
	P value	P value
Being on a Beta Blocker	0.57 (0.38-0.85)	0.55 (0.36-0.83)
	0.006	0.005
Liver Frailty Index	1.52 (1.13-2.03)	1.35 (1.02-1.80)
	0.005	0.04
MELD score	1.03 (0.99-1.07)
	0.19
Creatinine	1.17 (1.07-1.28)	1.10 (1.00-1.22)
	0.001	0.006
Albumin	0.79 (0.56-1.12)
	0.18
Sodium	0.99 (0.95-1.04)
	0.76
HCC	0.80 (0.50-1.29)
	0.37
Ascites	0.98 (0.63-1.51)
	0.92
Age	1.02 (0.99-1.04)
	0.15
Gender (female)	1.09 (0.72-1.65)
	0.68
Hepatic encephalopathy	1.99 (1.30-3.05)	1.64 (1.05-2.57)
(> 60 s)	0.001	0.03

HCC: Hepatocellular carcinoma; MELD: Model for End Stage Liver Disease; SHR: subdistribution hazard ratio.